Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
Public ClinicalTrials.gov record NCT04072445. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Trial of Trifluridine/Tipiracil in Combination With Irinotecan in Biliary Tract Cancers
Study identification
- NCT ID
- NCT04072445
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Mayo Clinic
- Other
- Enrollment
- 28 participants
Conditions and interventions
Conditions
- Advanced Bile Duct Carcinoma
- Advanced Gallbladder Carcinoma
- Refractory Bile Duct Carcinoma
- Refractory Gallbladder Carcinoma
- Stage III Distal Bile Duct Cancer AJCC v8
- Stage III Gallbladder Cancer AJCC v8
- Stage III Intrahepatic Bile Duct Cancer AJCC v8
- Stage IIIA Distal Bile Duct Cancer AJCC v8
- Stage IIIA Gallbladder Cancer AJCC v8
- Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8
- Stage IIIB Distal Bile Duct Cancer AJCC v8
- Stage IIIB Gallbladder Cancer AJCC v8
- Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8
- Stage IV Distal Bile Duct Cancer AJCC v8
- Stage IV Gallbladder Cancer AJCC v8
- Stage IV Intrahepatic Bile Duct Cancer AJCC v8
- Stage IVA Gallbladder Cancer AJCC v8
- Stage IVB Gallbladder Cancer AJCC v8
Interventions
- Irinotecan Drug
- Irinotecan Hydrochloride Drug
- Trifluridine and Tipiracil Hydrochloride Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 17, 2019
- Primary completion
- Aug 12, 2021
- Completion
- Aug 12, 2021
- Last update posted
- Aug 8, 2023
2019 – 2021
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04072445, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 8, 2023 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04072445 live on ClinicalTrials.gov.